50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Is There Value In These Growth Stocks?
SunPower Is Ready To Power Up Triple-Digit Earnings Gains
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Is There Value In These Growth Stocks?
SunPower Is Ready To Power Up Triple-Digit Earnings Gains
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Is There Value In These Growth Stocks?
SunPower Is Ready To Power Up Triple-Digit Earnings Gains
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Is There Value In These Growth Stocks?
SunPower Is Ready To Power Up Triple-Digit Earnings Gains
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What The White House Is NOT Telling You About The "Green Revolution." (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage

Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

$7.81
+0.32 (+4.27%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.49
$7.85
50-Day Range
$6.04
$9.66
52-Week Range
$3.53
$10.02
Volume
180,496 shs
Average Volume
325,538 shs
Market Capitalization
$343.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Eiger BioPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
514.6% Upside
$48.00 Price Target
Short Interest
Healthy
3.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
1.40mentions of Eiger BioPharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$49,050 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

125th out of 1,071 stocks

Biological Products, Except Diagnostic Industry

20th out of 172 stocks

EIGR stock logo

About Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Eiger BioPharmaceuticals, Inc. (EIGR)
Eiger BioPharmaceuticals Inc - Stock Quote EIGR
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Company Calendar

Last Earnings
8/04/2022
Today
9/28/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+514.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,920,000.00
Net Margins
-672.48%
Pretax Margin
-672.02%

Debt

Sales & Book Value

Annual Sales
$12.14 million
Book Value
$2.13 per share

Miscellaneous

Free Float
40,713,000
Market Cap
$343.41 million
Optionable
Not Optionable
Beta
1.68

Key Executives

  • Mr. David A. Cory M.B.A. (Age 58)
    MBA, R.Ph, R.Ph., Bus. Founder, Pres, CEO & Director
    Comp: $1.02M
  • Dr. Jeffrey S. Glenn M.D. (Age 59)
    Ph.D., Scientific Founder & Independent Director
    Comp: $57.5k
  • Mr. Sriram Ryali M.B.A. (Age 41)
    Chief Financial Officer
    Comp: $662.94k
  • Mr. Eldon C. Mayer IIIMr. Eldon C. Mayer III (Age 61)
    M.B.A., Exec. VP & Chief Commercial Officer
    Comp: $576.18k
  • Mr. Christopher A. Kurtz (Age 55)
    Chief Technical Officer
  • Mr. Erik Atkisson (Age 50)
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Dr. Ingrid C. Choong
    Sr. VP of Clinical Devel.
  • Dr. Stephana E. Patton J.D. (Age 51)
    Ph.D., Consultant
  • Mr. Rich Franco M.B.A.
    Sr. VP of Regulatory Affairs
  • Dr. Colin Hislop M.D. (Age 64)
    Sr. VP of Clinical & Devel. Operations













EIGR Stock - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price forecast for 2022?

1 analysts have issued 1-year price objectives for Eiger BioPharmaceuticals' shares. Their EIGR share price forecasts range from $48.00 to $48.00. On average, they predict the company's share price to reach $48.00 in the next year. This suggests a possible upside of 514.6% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2022?

Eiger BioPharmaceuticals' stock was trading at $5.19 at the beginning of the year. Since then, EIGR stock has increased by 50.5% and is now trading at $7.81.
View the best growth stocks for 2022 here
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.20. The biotechnology company earned $4.09 million during the quarter, compared to analysts' expectations of $2.10 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 97.79% and a negative net margin of 672.48%. During the same period last year, the firm earned ($0.57) EPS.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (1.60%), Assenagon Asset Management S.A. (1.47%), Knott David M Jr (0.93%), Northern Trust Corp (0.89%), Goldman Sachs Group Inc. (0.58%) and DAVENPORT & Co LLC (0.52%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $7.81.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $343.38 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.

This page (NASDAQ:EIGR) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.